Cord Blood Registry® (CBR) recently made headlines by announcing that it had entered into a definitive agreement to be acquired by AMAG Pharmaceuticals for $700M. While the announcement was new, there were aspects of the deal that seemed eerily familiar.
[Read more…]
Dental Pulp Stem Cell News Round-Up | 3rd Quarter 2015
The dental pulp stem cell industry is a rapidly evolving industry. Every month there are major events occurring in the sector that shift industry dynamics. Often, these events are announcements of technical or scientific advancements. Sometimes they are announcements of major industry alliances. Occasionally, they are announcements of a new industry competitor, a major milestone, or a significant funding award.
For those of us interested in the dental pulp stem cell industry, tracking these shifting industry dynamics is of paramount importance. For this reason, this post covers the most significant neural stem cell industry news events as of July 2015.
5 Types of Cord Blood Market Participants Impacted by AMAG Pharma’s Acquisition of Cord Blood Registry (CBR®)
On June 29, 2015, AMAG Pharmaceuticals released news that reverberated throughout the cord blood banking industry worldwide, announcing that it had entered into a definitive agreement to acquire Cord Blood Registry (CBR®) for $700 million. The acquisition is expected to close during the third-quarter of 2015, based on regulatory approvals and execution of agreed upon terms and conditions.
Direct Participants in the Cord Blood Deal
Founded in 1992 and headquartered in San Bruno, California, Cord Blood Registry® is the largest cord blood bank in the United States and the world. CBR® currently stores over 500,000 preserved cord blood and cord tissue units, which is substantially more than its nearest competitor, ViaCord, which has approximately 350,000 units stored. [Read more…]
[ALLIANCE] Sistemic and RoosterBio Developing Regenerative Technologies Involving miRNA and Mesenchymal Stem/Stromal Cells
Short Summary: RoosterBio, Inc. and Sistemic have entered into an agreement to synergistically develop microRNA (miRNA)-based cell characterization technologies that will create more precise and relevant characterization panels for human mesenchymal stem cell (hMSC) products and in process cell banks.
[Read more…]
“Blockbuster” Year for Induced Pluripotent Stem Cells Provides Expanding Opportunities, with Japan at the Forefront of Global Innovation
To create profitable products and services, stem cell industry executives need to stay informed about rapidly-evolving industry trends. For this reason, this post explores important trends, events, and metrics of importance within the induced pluripotent stem cell (iPSC) industry. It also considers geographical dominance within the industry.
[Read more…]
